EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access

Expanding access to colorectal cancer screening through community pharmacies: Study protocol for the PharmFIT™ randomized controlled trial

Morgan Glascock, Mary Wangen, Renée M Ferrari, Meghan C O'Leary, Jessie Schwartz, Michelle Ndugulile, Joseph M Unger, Li Li, Macary Weck Marciniak, Daniel S Reuland, Kate Watabayashi, Alison T Brenner und 2 weitere

Contemporary Clinical Trials · 2026-11 · 170 · 108443

DOI: 10.1016/j.cct.2026.108443 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2026-11. Verfasst von Morgan Glascock und 13 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutchinson Cancer Center, Seattle, WA, United States of America. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Early Detection of Cancer, Community Pharmacy Services, Health Services Accessibility. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Fred Hutchinson Cancer Center, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Colorectal cancer (CRC) is a leading cause of cancer death. Fecal immunochemical test (FIT) screening remains underused, particularly in underserved communities. Community pharmacies are highly accessible and increasingly deliver preventive care, yet pharmacy-based CRC screening has not been tested in a large pragmatic randomized trial with concurrent implementation and economic evaluation. This protocol describes a pragmatic trial testing a pharmacy-based CRC screening intervention using FIT, called PharmFIT™, which integrates community pharmacies into CRC screening pathways for primary care patients due for screening. METHODS: PharmFIT™ is a two-arm, pragmatic, hybrid type 1 effectiveness-implementation trial in two geographically disparate states (Washington and North Carolina). Adults aged 45-75 years, due for CRC screening, are randomized (n = 1200) to PharmFIT™ or usual care. In the intervention arm, clinics recommend CRC screening and refer participants to partner pharmacies, and pharmacists counsel participants, dispense FIT kits, and support kit return and follow-up. The primary outcome is completion of any United States Preventive Services Task Force-recommended CRC screening test within 6 months. Secondary outcomes include reach, timeliness of FIT completion and follow-up colonoscopy, and screening differences across participant subgroups. Implementation outcomes (acceptability, appropriateness, feasibility, fidelity, cost) are assessed using mixed methods, and economic analyses estimate intervention implementation costs, incremental cost per additional participant screened, and budget impact conducted from pharmacy and societal perspectives. CONCLUSIONS: PharmFIT™ will provide effectiveness, implementation, and cost evidence for pharmacy-based CRC screening, informing the scalability of pharmacist-led cancer prevention within primary care. TRIAL REGISTRATION: ClinicalTrials.gov (NCT06656936).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsEarly Detection of CancerCommunity Pharmacy ServicesHealth Services AccessibilityHumansOccult BloodAgedMiddle AgedPragmatic Clinical Trials as TopicNorth CarolinaFemaleMaleCost-Benefit AnalysisPrimary Health CareRandomized Controlled Trials as TopicMass Screening

Stichwörter der Autor:innen

CRC screeningColorectal cancer screeningCommunity pharmacyEconomic evaluationFITFecal immunochemical testHybrid effectiveness–implementation trialImplementation sciencePragmatic randomized controlled trial

Autor:innen und Institutionen

  • Fred Hutchinson Cancer Center, Seattle, WA, United States of America.
  • University of North Carolina, Chapel Hill, NC, United States of America.
  • Fred Hutchinson Cancer Center, Seattle, WA, United States of America. Electronic address: pshah@fredhutch.org.

Förderung

  • NCI NIH HHS
  • Fred Hutchinson Cancer Center
  • National Institutes of Health National Cancer Institute

Zitieren

APA

Glascock, M., Wangen, M., Ferrari, R. M., O'Leary, M. C., Schwartz, J., Ndugulile, M., Unger, J. M., Li, L., Marciniak, M. W., Reuland, D. S., Watabayashi, K., Brenner, A. T., Wheeler, S. B., & Shah, P. D. (2026). Expanding access to colorectal cancer screening through community pharmacies: Study protocol for the PharmFIT™ randomized controlled trial. Contemporary Clinical Trials, 170, 108443. https://doi.org/10.1016/j.cct.2026.108443

Vancouver

Glascock M, Wangen M, Ferrari RM, O'Leary MC, Schwartz J, Ndugulile M, et al. Expanding access to colorectal cancer screening through community pharmacies: Study protocol for the PharmFIT™ randomized controlled trial. Contemporary Clinical Trials. 2026;170:108443. doi:10.1016/j.cct.2026.108443

BibTeX
@article{Glascock2026,
  author = {Glascock, Morgan and Wangen, Mary and Ferrari, Renée M and O'Leary, Meghan C and Schwartz, Jessie and Ndugulile, Michelle and Unger, Joseph M and Li, Li and Marciniak, Macary Weck and Reuland, Daniel S and Watabayashi, Kate and Brenner, Alison T and Wheeler, Stephanie B and Shah, Parth D},
  title = {Expanding access to colorectal cancer screening through community pharmacies: Study protocol for the PharmFIT™ randomized controlled trial},
  journal = {Contemporary Clinical Trials},
  year = {2026},
  volume = {170},
  pages = {108443},
  doi = {10.1016/j.cct.2026.108443}
}
Kostenlos starten →